A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

Summary

This phase 1 study will consist of two parts: Phase 1a is a single-dose study, and will evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) in healthy participants. Phase 1b is a multiple doses study, and will evaluate the safety, tolerability, PK and preliminary PD in participants with rheumatoid arthritis (RA).

Timeline

Start

2024-01-06

Primary completion

2025-01-10

Completion

2025-01-10

Drugs

Indications